A Call to Action: Empowering Pharmacists in Drug-Resistant Tuberculosis Management
- PMID: 40546291
- PMCID: PMC12182067
- DOI: 10.2147/JMDH.S517965
A Call to Action: Empowering Pharmacists in Drug-Resistant Tuberculosis Management
Abstract
Drug-resistant tuberculosis (DR-TB) continues to be a major global health threat, and while advancements in drug therapies have been made, the role of pharmacists in improving patient outcomes has not been fully optimized. This review aims to describe the types, resistance mechanisms, and management strategies of DR-TB, with a focus on discussing the critical role of pharmacists in optimizing treatment outcomes for DR-TB patients. A narrative review approach was adopted to provide an updated and evidence-based perspective. Additionally, manual review of reference lists from the retrieved articles was performed to identify additional relevant studies. The review identifies types of DR-TB, including mono-, poly-, rifampicin-, multi-, pre-extensively, and extensively-drug resistance. Resistance mechanisms are outlined, highlighting mutations in key genes, such as those involved in rifampicin and isoniazid (INH) resistance, which compromise treatment efficacy. The treatment regimens for DR-TB include the INH-R regimen, Bedaquiline, Pretomanid, and Linezolid (with or without Moxifloxacin) (BPaL(M) regimen, shorter oral regimen, and longer oral regimen, each tailored to the specific resistance pattern and patient condition. The challenges in managing DR-TB include complex treatment regimens and side effects, social barriers such as stigma and adherence issues, and system-related obstacles like limited resources and healthcare infrastructure. The review underscores pharmacists' vital yet underutilized role in addressing challenges. Pharmacists' contributions include patient counseling to improve adherence, and optimizing regimens for vulnerable populations and therapeutic drug monitoring. Addressing DR-TB requires a multifaceted approach, with pharmacists playing a critical role in its management. Their contributions are key to improving patient outcomes and overcoming the challenges associated with DR-TB management.
Keywords: adherence; drug-resistant; medication management; pharmacists; therapeutic drug monitoring; tuberculosis.
© 2025 Alfaqeeh et al.
Conflict of interest statement
The authors declare no conflicts of interest in this work.
Figures

Similar articles
-
Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.Cochrane Database Syst Rev. 2022 Apr 26;4(4):CD014877. doi: 10.1002/14651858.CD014877.pub2. Cochrane Database Syst Rev. 2022. PMID: 35470432 Free PMC article.
-
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.Cochrane Database Syst Rev. 2022 May 18;5(5):CD014841. doi: 10.1002/14651858.CD014841.pub2. Cochrane Database Syst Rev. 2022. PMID: 35583175 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.Cochrane Database Syst Rev. 2018 Aug 27;8(8):CD012768. doi: 10.1002/14651858.CD012768.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2021 Jan 15;1:CD012768. doi: 10.1002/14651858.CD012768.pub3. PMID: 30148542 Free PMC article. Updated.
-
Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review.GMS Hyg Infect Control. 2025 Jun 26;20:Doc33. doi: 10.3205/dgkh000562. eCollection 2025. GMS Hyg Infect Control. 2025. PMID: 40657634 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous